The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis
- 4 June 2021
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 125 (3) , 390-401
Abstract
Background Hypoxia-induced angiogenesis functions importantly in anaplastic thyroid cancer (ATC) progression. However, the therapeutic potential of broad-spectrum anti-angiogenic agent remains undefined. Anlotinib conventionally targets VEGFR, FGFR and PDGFR. Here, a novel role of anlotinib on ATC angiogenesis was illustrated. Methods Molecular expressions were established via tissue microarray. Multiple assays (tubule formation, 3D sprouting and chicken chorioallantoic membrane model) were used for angiogenic evaluation. Panels of molecular screening were achieved by antibody and PCR arrays. The loop binding motif of EGFR for homology modelling was prepared using Maestro. Results Anlotinib could dose- and time-dependently inhibit cell viability under normoxia and hypoxia and could repress hypoxia-activated angiogenesis more efficiently in vitro and in vivo. CXCL11 and phospho-EGFR were hypoxia-upregulated with a positive correlation. The cancer–endothelium crosstalk could be mediated by the positive CXCL11-EGF-EGFR feedback loop, which could be blocked by anlotinib directly targeting EGFR via a dual mechanism by simultaneous inhibitory effects on cancer and endothelial cells. The AKT-mTOR pathway was involved in this regulatory network. Conclusions The newly identified CXCL11-EGF-EGFR signalling provided mechanistic insight into the interaction between cancer and endothelial cells under hypoxia, and EGFR was a novel target. Anlotinib may be the encouraging therapeutic candidate in ATC.Keywords
Funding Information
- Nature Science Foundation of China
This publication has 49 references indexed in Scilit:
- Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12Cytokine & Growth Factor Reviews, 2013
- The IL-8–Regulated Chemokine Receptor CXCR7 Stimulates EGFR Signaling to Promote Prostate Cancer GrowthCancer Research, 2011
- Hypoxia-Inducible Factors and the Response to Hypoxic StressMolecular Cell, 2010
- A Phase II Study of Imatinib in Patients with Advanced Anaplastic Thyroid CancerThyroid®, 2010
- Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapyCancer Immunology, Immunotherapy, 2010
- Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging TherapiesClinical Oncology, 2010
- CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculatureProceedings of the National Academy of Sciences, 2007
- The role of the EGFR signaling in tumor microenvironmentJournal of Cellular Physiology, 2007
- Epidermal Growth Factor Receptor as a Novel Therapeutic Target in Anaplastic Thyroid CarcinomasAnnals of the New York Academy of Sciences, 2004
- The basic-helix–loop–helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factorsProceedings of the National Academy of Sciences, 1998